|Series D, 10/2010 |
Hopen Life Sciences
|Partial Close, 8/2011 ||$6.81M|
|Venture Round, 2/2014 ||$98.2k|
|Debt, 8/2012 ||$2.5M|
Metabolic Solutions Development Company (www.msdrx.com), based in Kalamazoo, Mich., is developing innovative therapeutics based upon a novel pharmacological path to treat type 2 diabetes. This innovative approach seeks to improve the efficacy of treatment by freeing patients from the adverse side effects of current treatments, including edema and weight gain. The companyâ€™s scientific strategy is built on a historical understanding of insulin-sensitizers and its unique insight into the mechanism of insulin-sensitizing pharmacology. The company believes that its efforts will result in the creation of a new generation of superior, safer drug therapies to treat type 2 diabetes and other serious metabolic disorders.